New drug combo aims to stop Graft-Versus-Host disease and leukemia return after transplant
NCT ID NCT07548983
First seen Apr 28, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This early-phase study tests whether giving ruxolitinib followed by ruxolitinib plus azacitidine after a stem cell transplant is safe for adults with acute myeloid leukemia (AML). The goal is to prevent graft-versus-host disease (a common transplant complication) and delay or stop the cancer from coming back. About 40 participants will be enrolled to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.